FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210343399> ?p ?o ?g. }

• W4210343399 endingPage "6" @default.
• W4210343399 startingPage "1" @default.
• W4210343399 abstract "Introduction: The Sodium-Glucose Cotransporter-2 Inhibitor (SGLT-2 inhibitor) is a diabetic medication. Recently, there has been enough evidence of SGLT-2 inhibitors in type 2 diabetes mellitus, driving in an abatement in cardiovascular breakdown hospitalization. To explore SGLT-2 inhibitor in cardiovascular breakdown with lower discharge portion, we led an orderly survey and meta-examination. Strategies: We played out a methodical writing search from various electronic databases. We used keywords:” SGLT-2 inhibitor '' and “Heart Failure.” Inclusion criteria are randomized placebo-controlled trial, one-year follow-up and ejection fraction 40% or less. Composite endpoint is cardiovascular mortality with hospitalization of heart failure. Individual outcomes include all-cause mortality, cardiovascular passing, and cardiovascular breakdown hospitalization. For low heterogeneity scores, results are introduced utilizing a danger proportion (RR) with a 95 percent certainty stretch and statistical analysis using a fixed-effect model.&#x0D; Results: Total of two randomized control trial was selected (DAPA-HF [Dapagliflozin] and EMPEROR-Reduced [Empagliflozin]) with 8,474 patients pooled within our analysis. The results of the composite outcome compared SGLT-2 inhibitor with placebo had significant decrease in the composite of cardiovascular passing with hospitalization of cardiovascular breakdown (RR=0.78 [95% CI, 0.71–0.84], p<0.00001; I2=0%). Result of individual outcome showed significant reduction of all-cause mortality (RR=0.88 [95% CI, 0.79 – 0.98], p=0.03; I2=1%), cardiovascular mortality (RR=0.87 [95% CI, 0.77 – 0.99], p=0.03; I2=0%) and hospitalization of heart failure (RR=0.72 [95% CI, 0.65–0.81], p<0.00001; I2=0%). Conclusion: Within one year of treatment with an SGLT-2 inhibitor, the composite of cardiovascular passing with cardiovascular breakdown hospitalization, all-cause mortality, cardiovascular mortality, and cardiovascular breakdown hospitalization was significantly reduced." @default.
• W4210343399 created "2022-02-08" @default.
• W4210343399 creator A5020541655 @default.
• W4210343399 creator A5031169541 @default.
• W4210343399 creator A5038164660 @default.
• W4210343399 creator A5044537247 @default.
• W4210343399 creator A5087640018 @default.
• W4210343399 date "2022-01-09" @default.
• W4210343399 modified "2023-09-26" @default.
• W4210343399 title "A Systematic Review and Meta-analysis of Randomized Placebo-controlled Trials 1 Year after Starting Sodium-glucose Transporter-2 Inhibitors in Heart Failure Patients with Reduced Ventricular Ejection Fraction" @default.
• W4210343399 cites W1770274352 @default.
• W4210343399 cites W2011556287 @default.
• W4210343399 cites W2128606426 @default.
• W4210343399 cites W2146264128 @default.
• W4210343399 cites W2187514862 @default.
• W4210343399 cites W2412800896 @default.
• W4210343399 cites W2416348735 @default.
• W4210343399 cites W2463195288 @default.
• W4210343399 cites W2538443876 @default.
• W4210343399 cites W2581663237 @default.
• W4210343399 cites W2582603147 @default.
• W4210343399 cites W2599208859 @default.
• W4210343399 cites W2618856448 @default.
• W4210343399 cites W2626446274 @default.
• W4210343399 cites W2888544493 @default.
• W4210343399 cites W2913619273 @default.
• W4210343399 cites W2921866736 @default.
• W4210343399 cites W2925036255 @default.
• W4210343399 cites W2939222610 @default.
• W4210343399 cites W2940024069 @default.
• W4210343399 cites W2953473968 @default.
• W4210343399 cites W2974260792 @default.
• W4210343399 cites W2988212132 @default.
• W4210343399 cites W3015179476 @default.
• W4210343399 cites W3037876601 @default.
• W4210343399 cites W3081830235 @default.
• W4210343399 doi "https://doi.org/10.3889/oamjms.2022.8017" @default.
• W4210343399 hasPublicationYear "2022" @default.
• W4210343399 type Work @default.
• W4210343399 citedByCount "0" @default.
• W4210343399 crossrefType "journal-article" @default.
• W4210343399 hasAuthorship W4210343399A5020541655 @default.
• W4210343399 hasAuthorship W4210343399A5031169541 @default.
• W4210343399 hasAuthorship W4210343399A5038164660 @default.
• W4210343399 hasAuthorship W4210343399A5044537247 @default.
• W4210343399 hasAuthorship W4210343399A5087640018 @default.
• W4210343399 hasBestOaLocation W42103433991 @default.
• W4210343399 hasConcept C126322002 @default.
• W4210343399 hasConcept C134018914 @default.
• W4210343399 hasConcept C142724271 @default.
• W4210343399 hasConcept C164705383 @default.
• W4210343399 hasConcept C168563851 @default.
• W4210343399 hasConcept C203092338 @default.
• W4210343399 hasConcept C204787440 @default.
• W4210343399 hasConcept C207103383 @default.
• W4210343399 hasConcept C27081682 @default.
• W4210343399 hasConcept C2775887513 @default.
• W4210343399 hasConcept C2777180221 @default.
• W4210343399 hasConcept C2777422806 @default.
• W4210343399 hasConcept C2778198053 @default.
• W4210343399 hasConcept C44249647 @default.
• W4210343399 hasConcept C555293320 @default.
• W4210343399 hasConcept C71924100 @default.
• W4210343399 hasConcept C78085059 @default.
• W4210343399 hasConcept C82789193 @default.
• W4210343399 hasConcept C95190672 @default.
• W4210343399 hasConceptScore W4210343399C126322002 @default.
• W4210343399 hasConceptScore W4210343399C134018914 @default.
• W4210343399 hasConceptScore W4210343399C142724271 @default.
• W4210343399 hasConceptScore W4210343399C164705383 @default.
• W4210343399 hasConceptScore W4210343399C168563851 @default.
• W4210343399 hasConceptScore W4210343399C203092338 @default.
• W4210343399 hasConceptScore W4210343399C204787440 @default.
• W4210343399 hasConceptScore W4210343399C207103383 @default.
• W4210343399 hasConceptScore W4210343399C27081682 @default.
• W4210343399 hasConceptScore W4210343399C2775887513 @default.
• W4210343399 hasConceptScore W4210343399C2777180221 @default.
• W4210343399 hasConceptScore W4210343399C2777422806 @default.
• W4210343399 hasConceptScore W4210343399C2778198053 @default.
• W4210343399 hasConceptScore W4210343399C44249647 @default.
• W4210343399 hasConceptScore W4210343399C555293320 @default.
• W4210343399 hasConceptScore W4210343399C71924100 @default.
• W4210343399 hasConceptScore W4210343399C78085059 @default.
• W4210343399 hasConceptScore W4210343399C82789193 @default.
• W4210343399 hasConceptScore W4210343399C95190672 @default.
• W4210343399 hasIssue "F" @default.
• W4210343399 hasLocation W42103433991 @default.
• W4210343399 hasOpenAccess W4210343399 @default.
• W4210343399 hasPrimaryLocation W42103433991 @default.
• W4210343399 hasRelatedWork W3013207865 @default.
• W4210343399 hasRelatedWork W3104942557 @default.
• W4210343399 hasRelatedWork W3111618423 @default.
• W4210343399 hasRelatedWork W3201939689 @default.
• W4210343399 hasRelatedWork W3215515955 @default.
• W4210343399 hasRelatedWork W4200586754 @default.
• W4210343399 hasRelatedWork W4210427521 @default.
• W4210343399 hasRelatedWork W4225666519 @default.
• W4210343399 hasRelatedWork W4283736861 @default.

• next